Pharmacokinetics and anti-HIV-1 efficacy of negatively charged human serum albumins in mice

M E Kuipers, P J Swart, Martin Schutten, C Smit, J H Proost, A D Osterhaus, D K Meijer

    Research output: Contribution to journalArticleAcademicpeer-review

    11 Citations (Scopus)

    Abstract

    Negatively charged albumins (NCAs, with the prototypes succinylated human serum albumin (Suc-HSA) and aconitylated human serum albumin (Aco-HSA)), modified proteins with a potent anti-human immunodeficiency virus type 1 (anti-HIV-1) activity in vitro, were studied for their pharmacokinetic behaviour in mice and their in vivo anti-HIV-1 efficacy in an HIV-1 infection model in mice. In contrast to the saturation kinetics found in rats, intravenous injections of 10-300 mg/kg for both NCAs showed a linear correlation between the area under the curve (AUC) and the dose. The elimination t1/2 was 25 and 30 min for Suc-HSA and Aco-HSA, respectively. Preinjections of an excess of formaldehyde-treated albumin (Form-HSA) resulted in plasma levels that were 3- and 4-fold higher for Aco-HSA and Suc-HSA, respectively. These data indicate that elimination is at least partly (scavenger) receptor-mediated. Organ distribution studies 10 min after injection showed an accumulation in liver (Suc-HSA 17.3 +/- 6.6% of the dose; Aco-HSA 20.9 +/- 2.3%) and lungs (Suc-HSA 12.7 +/- 10.5%; Aco-HSA 16.0 +/- 13.6). Intraperitoneal injection of 300 mg/kg Suc-HSA resulted in a final bioavailability of about 0.45. Suc-HSA was also evaluated for its in vivo neutralizing capacity in a human-to-mouse chimeric model for HIV-1 infection. Intraperitoneal injections of 300 and 3 mg/kg Suc-HSA, given 15-30 min before the mice were challenged with the virus, sufficed to protect these mice against infection with the HIV-1 IIIB strain.

    Original languageEnglish
    Pages (from-to)99-108
    Number of pages10
    JournalAntiviral Research
    Volume33
    Issue number2
    Publication statusPublished - Jan-1997

    Keywords

    • human immunodeficiency virus type 1
    • negatively charged human serum albumins
    • antiviral
    • polyanion
    • IMMUNODEFICIENCY-VIRUS INFECTION
    • DEXTRAN SULFATE
    • HIV-INFECTION
    • THERAPY
    • GP120
    • INHIBITOR
    • PROTEASE
    • PROTEINS
    • INVITRO
    • BINDING

    Cite this